Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques

Nuclear Medicine and Biology

Volumn 39, Issue 8, 2012, Pages 1232-1235

  Noda, Akihiro ^a   Fushiki, Hiroshi ^a   Murakami, Yoshihiro ^a   Sasaki, Hiroshi ^a   Miyoshi, Sosuke ^a   Kakuta, Hirotoshi ^a   Nishimura, Shintaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Positron emission tomography; Rhesus macaque; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CARBON 11; DRUG METABOLITE; TELMISARTAN;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG PENETRATION; MALE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; RADIOACTIVITY; RECEPTOR BLOCKING; RHESUS MONKEY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL TRANSPORT; BRAIN; CARBON RADIOISOTOPES; CONSCIOUSNESS; MACACA MULATTA; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84867866631     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.06.012     Document Type: Article

References (35)

1. Destro M., Cagnoni F., Dognini G.P., Galimberti V., Taietti C., Cavalleri C., et al. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother 2011, 12:2719-2735.
2. Gosse P. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Vasc Health Risk Manag 2006, 2:195-201.
3. Galzerano D., Capogrosso C., Di Michele S., Galzerano A., Paparello P., Lama D., et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010, 6:113-133.
4. Kakuta H., Sudoh K., Sasamata M., Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005, 25:41-46.
5. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
6. Takasu T., Kakuta H., Sasamata M., Yamagishi S. An angiotensin II (Ang II) type 1 receptor blocker, telmisartan, improves insulin resistance in KK-Ay diabetic mice. Int J Biomed Sci 2006, 2:333-336.
7. Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005, 54:3442-3452.
8. de Luis D.A., Conde R., Gonzalez-Sagrado M., Aller R., Izaola O., Duenas A., et al. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp 2010, 25:275-279.
9. Derosa G., Fogari E., D'Angelo A., Cicero A.F., Salvadeo S.A., Ragonesi P.D., et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007, 32:261-268.
10. Negro R., Formoso G., Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006, 29:957-961.
11. Iwai M., Liu H.W., Chen R., Ide A., Okamoto S., Hata R., et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004, 110:843-848.
12. Saavedra J.M., Benicky J., Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell Mol Neurobiol 2006, 26:1099-1111.
13. Thone-Reineke C., Steckelings U.M., Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006, 24:S115-S121.
14. Thone-Reineke C., Zimmermann M., Neumann C., Krikov M., Li J., Gerova N., et al. Are angiotensin receptor blockers neuroprotective?. Curr Hypertens Rep 2004, 6:257-266.
15. Wilms H., Rosenstiel P., Unger T., Deuschl G., Lucius R. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs 2005, 5:245-253.
16. Gard P.R. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 2004, 8:7-14.
17. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
18. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
19. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
20. Wright J.W., Harding J.W. Brain renin-angiotensin-a new look at an old system. Prog Neurobiol 2011, 95:49-67.
21. Iwai M., Inaba S., Tomono Y., Kanno H., Iwanami J., Mogi M., et al. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res 2008, 31:161-168.
22. Kasahara Y., Taguchi A., Uno H., Nakano A., Nakagomi T., Hirose H., et al. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res 2010, 1340:70-80.
23. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakata A., Jing F., et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009, 54:782-787.
24. Gohlke P., Weiss S., Jansen A., Wienen W., Stangier J., Rascher W., et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001, 298:62-70.
25. Shimizu K., Takashima T., Yamane T., Sasaki M., Kageyama H., Hashizume Y., et al. Whole-body distribution and radiation dosimetry of [(11)C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl Med Biol 2012.
26. Iimori H., Hashizume Y., Sasaki M., Kajiwara Y., Sugimoto Y., Sugiyama Y., et al. First automatic radiosynthesis of 11C labeled telmisartan using a multipurpose synthesizer for clinical research use. Ann Nucl Med 2011, 25:333-337.
27. Onoe H., Inoue O., Suzuki K., Tsukada H., Itoh T., Mataga N., et al. Ketamine increases the striatal N-[11C]methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res 1994, 663:191-198.
28. Takechi H., Onoe H., Imamura K., Onoe K., Kakiuchi T., Nishiyama S., et al. Brain activation study by use of positron emission tomography in unanesthetized monkeys. Neurosci Lett 1994, 182:279-282.
29. Cross D.J., Minoshima S., Nishimura S., Noda A., Tsukada H., Kuhl D.E. Three-dimensional stereotactic surface projection analysis of macaque brain PET: development and initial applications. J Nucl Med 2000, 41:1879-1887.
30. Minoshima S., Foster N.L., Kuhl D.E. Posterior cingulate cortex in Alzheimer's disease. Lancet 1994, 344:895.
31. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995, 36:1238-1248.
32. Schmid J., Beschke K., Prox P., Ebner T., Busch U., Koebe H.G., et al. In vivo and in vitro biotransformation of telmisartan, human hepatocyte cultures as an aid in human metabolic studies. Exp Toxicol Pathol 1996, 48:387.
33. Noda A., Takamatsu H., Murakami Y., Yajima K., Tatsumi M., Ichise R., et al. Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. J Nucl Med 2003, 44:105-108.
34. Ohrui T., Tomita N., Sato-Nakagawa T., Matsui T., Maruyama M., Niwa K., et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004, 63:1324-1325.
35. Kume K., Hanyu H., Sakurai H., Takada Y., Onuma T., Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 2011.